| locally advanced NSCLC - (neo)adjuvant (NA) | metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | NSCLC neoadjuvant setting | ||||
| locally advanced NSCLC - (neo)adjuvant (NA) | mNSCLC - L1 - PDL1 negative | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - all population | non squamous - mNSCLC - L2 - all population | squamous - mNSCLC - L2 - all population | NSCLC neoadjuvant setting | |
| nivolumab based treatment | |||||||
| nivolumab alone | CheckMate 026 ... CheckMate 026 ... | CheckMate 078 | CheckMate 057 | CheckMate 017 | |||
| nivolumab plus SoC | CheckMate 227 ... | ||||||